An investigational antiviral drug currently undergoing human trials in Europe for treating hepatitis C infections may have potential to reduce muscle cell damage in Duchenne and other forms of muscular dystrophy.

A research team led by Cincinnati Children's Hospital Medical Center reported their results using three different mouse models of MD in a letter posted online March 16 by the journal Nature Medicine.